---
title: "Nuvation Bio Inc. (NUVB.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/NUVB.US.md"
symbol: "NUVB.US"
name: "Nuvation Bio Inc."
industry: "Pharmaceuticals"
datetime: "2026-05-20T16:46:38.081Z"
locales:
  - [en](https://longbridge.com/en/quote/NUVB.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/NUVB.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/NUVB.US.md)
---

# Nuvation Bio Inc. (NUVB.US)

## Company Overview

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company’s lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.nuvationbio.com](https://www.nuvationbio.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:13.000Z

**Overall: C (0.46)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 65 / 189 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 1205.52% |  |
| Net Profit YoY | 75.92% |  |
| P/B Ratio | 4.62 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 1476376357.04 |  |
| Revenue | 143046000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -39.51% | E |
| Profit Margin | -102.06% | E |
| Gross Margin | 92.80% | A |
| Revenue YoY | 1205.52% | A |
| Net Profit YoY | 75.92% | A |
| Total Assets YoY | 23.91% | A |
| Net Assets YoY | -23.82% | E |
| Cash Flow Margin | 86.12% | C |
| OCF YoY | 1205.52% | A |
| Turnover | 0.26 | D |
| Gearing Ratio | 47.63% | C |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Nuvation Bio Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "1205.52%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "75.92%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "4.62",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "1476376357.04",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "143046000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-39.51%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-102.06%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "92.80%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "1205.52%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "75.92%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "23.91%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "-23.82%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "86.12%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "1205.52%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.26",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "47.63%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -10.11 | 188/189 | - | - | - |
| PB | 4.62 | 145/189 | 6.10 | 4.91 | 2.04 |
| PS (TTM) | 10.32 | 116/189 | 88.70 | 71.43 | 27.98 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-14T04:00:00.000Z

Total Analysts: **10**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 7 | 70% |
| Overweight | 2 | 20% |
| Hold | 1 | 10% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 4.54 |
| Highest Target | 20.00 |
| Lowest Target | 7.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/NUVB.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/NUVB.US/norm.md)
- [Related News](https://longbridge.com/en/quote/NUVB.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/NUVB.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**